In an interview with Pharmacogenomics Reporter this week, Hakan Sakul provided a snapshot of Pfizer's efforts in personalized medicine, the company's stance on regulatory issues, and its overall focus on "omics"-guided medicine.
The HIV center, located in a New York City suburb, will allow Profectus in December to accommodate more than 20 new researchers it plans to hire over the next two years, in addition to the 13 now based in temporary space.
The agreement comes approximately three months after ABL and Stanford reached their own settlement in the suit, in which ABL accused the university and professor of breaching a patent immunity contract regarding Stanford's HIV Drug Resistance Database.
LabCorp's $107 million offer to acquire Monogram gives it access to molecular diagnostics and pharmacogenomic tests that are clinically validated and are free of regulatory challenges. Although Monogram wasn't looking to be acquired, the deal would allow broader marketing of its tests by using LabCorp's national infrastructure.